Nine Months 2019 Immunovia AB (publ) Earnings Call Transcript
Hello, and welcome to the Immunovia Q3 Report 2019. Today, I am pleased to present Mats Grahn, CEO. (Operator Instructions)
Mats, please begin.
()-
Thank you, and welcome to this Q3 2019 report conference. Agenda today, I will cover a bit of the financials and then we will talk, of course, about our core area, PanCan-d, pancreas cancer diagnosis. I will have a little special session today to give you more details on the process of going from an initial study in an area to market entry to give a context to our updates in general on our projects. And then after that, I'll move into the pipeline projects and, of course, a summary.
We have prepared slides to these presentations to give you further clarity to the talk, and there is a web link. There, you can click through IRR from the press release to this one. I hope you have been able to do that.
So then let's say, first, a few words about the financials. As you have seen in the report, we have a good position when it
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
